Implications of decreased serum adiponectin for type IIb hyperlipidaemia and increased cholesterol levels of very-low-density lipoprotein in Type II diabetic patients

Clinical Science

Volumn 109, Issue 3, 2005, Pages 297-302

  Yoshida, Hiroshi ^a,b   Hirowatari, Yuji ^c   Kurosawa, Hideo ^a   Tada, Noho ^a,b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOSOH CORPORATION   (Japan)

Author keywords

Adiponectin; HPLC; Triacylglycerol (triglyceride); Type II diabetes; VLDL (very low density lipoprotein) cholesterol

Indexed keywords

ADIPONECTIN; CHYLOMICRON; FIBRIC ACID DERIVATIVE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BODY MASS INDEX; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 25144472594     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040353     Document Type: Article

References (32)

1. Bechman, J. A., Creager, M. A. and Libby, P. (2002) Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, J. Am. Med. Assoc. 287, 2570-2581
2. Gotto, Jr, A. M. (2002) Lipid management in diabetic patients: Lessons from prevention trials. Am. J. Med. 112, 19S-26S
3. Stamler, J., Vaccaro, O., Neaton, J. D. and Wentworth, D. (1993) Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444
4. Haffner, S. M., Letho, S., Ronneman, T., Pyorala, K. and Laakso, M. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234
5. Colagiuri, S. and Best, J. (2002) Lipid-lowering therapy in people with type 2 diabetes. Curr. Opin. Lipidol. 13, 617-623
6. Taskinen, M. R. (2002) Diabetic dyslipidemia. Atherosclerosis Suppl. 3, 47-51
7. Lu, W., Resnick, H. E., Jablonski, K. A. et al. (2003) Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. Diabetes Care 26, 16-23
8. Goldberg, I. J. (2001) Diabetic dyslipidemia: causes and consequences. J. Clin. Endocrinol. Med. 86, 965-971
9. Hirowatari, Y., Yoshida, H., Kurosawa, H., Doumitsu, K. and Tada, N. (2003) Measurement of cholesterol of major serum lipoprotein classes by anion-exchange HPLC with perchlorate ion-containing eluent. J. Lipid Res. 44, 1404-1412
10. Hokanson, J. E. and Austin, M. A. (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3, 213-219
11. Devaraj, S., Vega, G., Lange, R., Grundy, S. M. and Jialal, I. (1998) Remnant-like particles' cholesterol levels in patients with dysbetalipoprotememia or coronary artery disease. Am. J. Med. 104, 445-450
12. Kugiyama, K., Doi, H., Takazoe, K. et al. (1999) Remnant lipoprotein levels in fasting serum predict coronary events in patients with coronary artery disease. Circulation 99, 2858-2860
13. Cohn, J. S., Marcoux, C. and Davignon, J. (1999) Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler., Thromb., Vasc. Biol. 19, 2474-2486
14. Iso, H., Naito, Y., Sato, S. et al. (2001) Serum triglyceride and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 153, 490-499
15. Fruchart, J. C. and Duriez, P. (2002) HDL and triglyceride as therapeutic targets. Curr. Opin. Lipidol. 13, 605-616
16. Havel, P. J. (2002) Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13, 51-59
17. Matsuzawa, Y., Funahashi, T., Kihara, S. and Shimomura, I. (2004) Adiponectin and metabolic syndrome. Arterioscler., Thromb., Vasc. Biol. 24, 29-33
18. Shimomura, I., Funahashi, T., Takahashi, M. et al. (1996) Enhanced expression of PAI-1 in visceral fat: possible contribution to vascular disease in obesity. Nat. Med. 2, 1-5
19. Arita, Y., Kihara, S., Ouchi, N. et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257, 79-83
20. Maeda, N., Takahashi, M., Funahashi, T. et al. (2001) PPARγ ligands increase expression and plasma concentration of adiponectin, an adipose-derived protein. Diabetes 50, 2094-2099
21. Hotta, K., Funahashi, T., Arita, Y. et al. (2000) Plasma concentration of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler., Thromb., Vasc. Biol. 20, 1595-1599
22. Mallamaci, F., Zoccali, C., Cuzzola, F. et al. (2002) Adiponectin and essential hypertension. J. Nephrol. 15, 507-511
23. Kumada, M., Kihara, S., Sumitsuji, S. et al. (2003) Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler., Thromb., Vasc. Biol. 23, 85-89
24. Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y. and Walsh, K. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr. Opin. Lipidol. 14, 561-566
25. Matsubara, M., Maruoka, S. and Katayose, S. (2002) Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87, 2764-2769
26. Yamamoto, Y., Hirose, H., Saito, I. et al. (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. 103, 137-142
27. Daimon, M., Oizumi, T., Saitoh, T. et al. (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care 26, 2015-2020
28. Kondo, H., Shimomura, I., Kumada, M. et al. (2002) Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 51, 2325-2328
29. Von Eynatten, M., Schneider, J. G., Humpert, P. M. et al. (2004) Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care 27, 2925-2929
30. Combs, T. P., Utpal, P. B., Berg, A. H. et al. (2004) A transgenic mouse with deletion in the collageneous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145, 367-383
31. Yamauchi, T., Kamon, J., Waki, H. et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946
32. Bajaj, M., Suraamornkul, S., Piper, P. et al. (2003) Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in Pioglitazone-treated type 2 diabetic patients. J. Clin. Endocrinol. Metab. 89, 200-206